Treatment of Stage 3 Rectosigmoid Cancer

Introduction to Treatment Approaches

The European Society for Medical Oncology recommends wide surgical resection with total mesorectal excision followed by adjuvant chemotherapy with a fluoropyrimidine plus oxaliplatin combination for stage 3 rectosigmoid cancer, with the decision regarding neoadjuvant chemoradiotherapy depending on tumor location and resectability 1, 2

For tumors ≤11 cm from the anal verge, consideration of neoadjuvant chemoradiotherapy is necessary, as stated by the European Society for Medical Oncology 3, 4
Preoperative staging with pelvic MRI or endorectal ultrasound is essential to determine T-stage, circumferential resection margin involvement, and nodal status, according to the European Society for Medical Oncology 3, 4

The European Society for Medical Oncology mandates total mesorectal excision for all rectal components, and a minimum of 12 lymph nodes must be examined to adequately stage the disease 1, 5
Wide surgical resection with at least 5 cm margins on either side of the tumor is recommended by the European Society for Medical Oncology 5, 6

The standard adjuvant regimen is oxaliplatin plus fluoropyrimidine combination for 6 months, as recommended by the European Society for Medical Oncology 1, 2
The European Society for Medical Oncology suggests preferred regimens, including FOLFOX4, mFOLFOX6, and XELOX, with evidence supporting oxaliplatin combinations from trials such as MOSAIC and NSABP C-07 1, 2, 6, 9

Postoperative chemoradiotherapy is no longer routinely recommended by the European Society for Medical Oncology but should be considered only in specific high-risk scenarios if preoperative radiotherapy was not given 3, 4

The evidence for adjuvant chemotherapy benefit in rectal cancer is less robust than in colon cancer, but for stage 3 disease, adjuvant chemotherapy remains standard practice based on extrapolation from colon cancer data, as stated by the European Society for Medical Oncology 1, 2, 3, 4
Inadequate mesorectal excision and failure to examine at least 12 lymph nodes can lead to higher local recurrence rates and inadequate staging, according to the European Society for Medical Oncology 5, 7, 8